# PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

> **NCT03299309** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Daniel Landi** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Medulloblastoma
- Recurrent Brain Tumor, Childhood
- Malignant Glioma

## Interventions

- **DRUG:** PEP-CMV

## Key facts

- **NCT ID:** NCT03299309
- **Lead sponsor:** Daniel Landi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-29
- **Primary completion:** 2023-04-27
- **Final completion:** 2026-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299309, "PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03299309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*